Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and lowers the price target from $8 to $7.
October 08, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Maravai LifeSciences but lowered the price target from $8 to $7, indicating a cautious outlook.
The lowering of the price target by Goldman Sachs suggests a less optimistic view on Maravai LifeSciences' future performance, which could lead to a negative short-term impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target may influence investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100